JETEMA, CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15,690 KRW | +4.60% |
|
+6.73% | +0.90% |
| Sales 2024 * | 74.5B 54.16M 4.34B | Sales 2025 * | 102B 74.44M 5.96B | Capitalization | 280B 204M 16.31B |
|---|---|---|---|---|---|
| Net income 2024 * | 1B 727K 58.21M | Net income 2025 * | 15B 10.9M 873M | EV / Sales 2024 * | 3.76 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.74 x |
| P/E ratio 2024 * |
151
x | P/E ratio 2025 * |
18
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.52% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.60% | ||
| 1 week | +6.73% | ||
| Current month | +13.12% | ||
| 1 month | +10.11% | ||
| 3 months | +8.96% | ||
| 6 months | -6.16% | ||
| Current year | +0.90% |
1 week
14 630.00
15 690.00
1 month
13 710.0015 690.00
Current year
13 600.0017 190.00
1 year
13 600.0028 950.00
3 years
9 730.0042 750.00
5 years
4 200.0042 750.00
10 years
4 200.0042 750.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jae-Young Kim
CEO | Chief Executive Officer | 56 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jae-Young Kim
CEO | Chief Executive Officer | 56 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 15,690 | +4.60% | 65,647 |
| 25/04/24 | 15,000 | +0.13% | 25,914 |
| 24/04/24 | 14,980 | -0.40% | 20,881 |
| 23/04/24 | 15,040 | -2.15% | 32,657 |
| 22/04/24 | 15,370 | +4.56% | 47,819 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
JETEMA. CO,.LTD is a Korea-based company principally engaged in the development and manufacturing of hyaluronic acid fillers used for facial beauty and other medical devices. The Company manufactures and sells medical devices for improvement of wrinkle, contour and volume. In addition, the Company also engages in the manufacturing and sale of laser equipment used for treatment of leukoplakia, psoriasis and alopecia areata, lifting medical device epiticons, cosmetic mask packs, pharmaceutical excaine creams as well as others.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +0.90% | 204M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- A216080 Stock
